Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer

Author(s):

Joyce O’Shaughnessy, MD,Laura Huppert, MD

Panelists discuss how aberrations in the PI3K/AKT/PTEN pathway drive treatment resistance and disease progression following first-line therapy in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the critical role of repeat biomarker testing to guide ongoing treatment strategies and enhance patient outcomes.

EP: 1.Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer

EP: 2.First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer

Now Viewing

EP: 3.Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer

EP: 4.Overview of the CAPItello-291 Trial

EP: 5.Clinical Experience with Capivasertib

EP: 6.Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy

EP: 7.Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia

EP: 8.Best Practices in Managing Patients on Capivasertib

Video content above is prompted by the following:

1. Dr Huppert: Could you discuss the role of the PI3K/AKT/PTEN pathway in driving resistance and progression after first-line treatment with CDK4/6 inhibitor plus endocrine therapy?

In normal cells, what is the role of the PI3K/AKT/PTEN pathway?
How might aberrations in the PI3K, AKT, or PTEN pathway contribute to treatment resistance and progression in hormone receptor–positive, HER2-negative advanced breast cancer?

2. Dr Huppert: Given the availability of new agents, what is your approach to repeat biomarker testing throughout treatment? What is the importance of repeat testing at each progression, and how can this inform treatment selection?